OKYO Pharma (OKYO) Competitors $1.43 +0.06 (+4.38%) Closing price 03/7/2025 04:00 PM EasternExtended Trading$1.45 +0.02 (+1.33%) As of 03/7/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends OKYO vs. PLX, GNFT, CTNM, CCCC, CRGX, LRMR, NBTX, NLTX, ENTA, and CDTXShould you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Protalix BioTherapeutics (PLX), Genfit (GNFT), Contineum Therapeutics (CTNM), C4 Therapeutics (CCCC), CARGO Therapeutics (CRGX), Larimar Therapeutics (LRMR), Nanobiotix (NBTX), Neoleukin Therapeutics (NLTX), Enanta Pharmaceuticals (ENTA), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. OKYO Pharma vs. Protalix BioTherapeutics Genfit Contineum Therapeutics C4 Therapeutics CARGO Therapeutics Larimar Therapeutics Nanobiotix Neoleukin Therapeutics Enanta Pharmaceuticals Cidara Therapeutics Protalix BioTherapeutics (NYSE:PLX) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations. Do insiders & institutionals believe in PLX or OKYO? 16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 6.3% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer PLX or OKYO? Protalix BioTherapeutics and OKYO Pharma both received 10 outperform votes by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 76.92% of users gave Protalix BioTherapeutics an outperform vote. CompanyUnderperformOutperformProtalix BioTherapeuticsOutperform Votes1076.92% Underperform Votes323.08% OKYO PharmaOutperform Votes10100.00% Underperform VotesNo Votes Does the media favor PLX or OKYO? In the previous week, Protalix BioTherapeutics had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 1 mentions for Protalix BioTherapeutics and 0 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.00 beat Protalix BioTherapeutics' score of -0.71 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Overall Sentiment Protalix BioTherapeutics Negative OKYO Pharma Neutral Do analysts recommend PLX or OKYO? Protalix BioTherapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 541.03%. OKYO Pharma has a consensus price target of $7.00, suggesting a potential upside of 389.51%. Given Protalix BioTherapeutics' higher possible upside, research analysts clearly believe Protalix BioTherapeutics is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PLX or OKYO more profitable? OKYO Pharma has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. OKYO Pharma's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% OKYO Pharma N/A N/A N/A Which has preferable earnings & valuation, PLX or OKYO? Protalix BioTherapeutics has higher revenue and earnings than OKYO Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$45.67M3.77$8.31M-$0.13-18.00OKYO PharmaN/AN/A-$16.83MN/AN/A Which has more volatility & risk, PLX or OKYO? Protalix BioTherapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500. SummaryProtalix BioTherapeutics and OKYO Pharma tied by winning 6 of the 12 factors compared between the two stocks. Remove Ads Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKYO vs. The Competition Export to ExcelMetricOKYO PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.39M$3.16B$5.86B$8.32BDividend YieldN/A1.47%4.89%4.02%P/E RatioN/A28.9425.1819.36Price / SalesN/A381.07377.82118.07Price / CashN/A168.6838.1234.62Price / Book-7.153.477.304.23Net Income-$16.83M-$71.72M$3.19B$247.13M7 Day Performance13.49%1.30%1.23%0.46%1 Month Performance30.00%-7.96%-5.06%-6.96%1 Year Performance-0.69%-22.62%13.02%2.83% OKYO Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKYOOKYO Pharma2.753 of 5 stars$1.43+4.4%$7.00+389.5%-0.7%$48.39MN/A0.007Gap UpPLXProtalix BioTherapeutics1.9943 of 5 stars$2.31-0.9%$15.00+549.4%+57.0%$170.10M$45.67M-17.77200High Trading VolumeGNFTGenfit2.1635 of 5 stars$3.40-2.0%$13.00+282.4%+1.2%$169.99M$76.06M0.00120Positive NewsGap UpHigh Trading VolumeCTNMContineum Therapeutics2.2333 of 5 stars$6.59-6.4%$29.25+343.9%N/A$169.88M$50M0.0031Analyst ForecastPositive NewsCCCCC4 Therapeutics2.1447 of 5 stars$2.40-11.4%$12.50+420.8%-78.5%$169.41M$33.67M-1.41150Gap DownCRGXCARGO Therapeutics2.3251 of 5 stars$3.68-2.1%$15.00+307.6%-87.1%$169.38MN/A-0.86116LRMRLarimar Therapeutics1.2869 of 5 stars$2.65-12.5%$20.13+659.4%-70.3%$169.09MN/A-2.3030Upcoming EarningsNews CoverageNBTXNanobiotix1.8884 of 5 stars$3.57+1.7%$12.00+236.1%-52.4%$168.27M$36.22M0.00100Positive NewsGap UpNLTXNeoleukin TherapeuticsN/A$17.69+3.5%N/A-53.6%$166.25MN/A-5.6990ENTAEnanta Pharmaceuticals4.1244 of 5 stars$7.33-5.8%$17.25+135.3%-53.1%$165.97M$66.59M-1.48160Positive NewsCDTXCidara Therapeutics3.7994 of 5 stars$23.05-7.4%$32.20+39.7%+71.2%$162.43M$44.65M-0.9090Earnings ReportAnalyst ForecastShort Interest ↑News CoverageGap Down Remove Ads Related Companies and Tools Related Companies PLX Alternatives GNFT Alternatives CTNM Alternatives CCCC Alternatives CRGX Alternatives LRMR Alternatives NBTX Alternatives NLTX Alternatives ENTA Alternatives CDTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OKYO) was last updated on 3/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA new coin is elbowing its way to the top of the crypto worldWith Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKYO Stock Alerts